Navigation Links
Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)
Date:5/17/2012

last week of the 12-week, double-blind maintenance phase, as determined by an 11-point pain rating scale or numerical rating scale (NRS; 0='no pain,' 10='pain as bad as you can imagine'). Safety assessments were performed on the open-label and double-blind safety populations (all patients who received greater than or equal to 1 dose of open-label and double-blind treatment, respectively). Treatment-emergent adverse events (TEAEs), defined as any AEs (new or worse in intensity) that occurred after the first intake of study drug during the open-label or double-blind phase, were monitored throughout the study.

In the open-label titration period, 459 patients received one or more doses of tapentadol ER and were included in the open-label safety population. At the start of the 3-week, open-label phase, the majority of patients (87.1 percent) reported severe pain (6 or more on the 11-point NRS) with a mean pain intensity of 7.3. By the end of the open-label phase, the mean pain intensity was reduced to 3.6. Treatment-emergent adverse events (TEAEs) experienced by 10 percent or more of patients during the open-label phase were nausea (24.4 percent), dizziness (17), constipation (11.8) and somnolence (10.7).

A total of 358 patients completed the open-label titration period; 318 were randomized and received one or more dose of study medication (n=152 for placebo, 166 for tapentadol ER).

Following randomization, during the double-blind treatment phase to week 12, pain increased in the placebo group (as demonstrated by the mean change in pain intensity of 1.3), while in the tapentadol ER group, efficacy was maintained, as indicated by the mean change in pain intensity of 0.28. The least-squares mean difference between the tapentadol ER and placebo groups in the change in average pain intensity was -0.95 on the 11-point NRS favoring tapentadol ER (95 percent CI, -1.42 to -0.49; p<0.001, tapentadol ER vs. placebo)(4).

For more details about the s
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
2. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
3. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
4. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
5. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
6. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
7. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
10. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
11. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 2015 LifeScienceIndustryResearch.com announces ... Industry and 2015 Deep Research Report on ... Pharmaceutical category in its database.  ... basic information, including definition, classification, application, industry ... news analysis, etc. Azithromycin Key Manufacturers Analysis ...
(Date:4/1/2015)... -- Jintian Pharmaceutical Group Limited ("Jintian Pharmaceutical" or the ... chairman and executive director purchased 40,000,000 ordinary shares (the ... entire issued share capital of the Company from AMG ... amount of approximately HK$113 million. Upon the completion of ... 45.17% to 47.17%. Mr. Jin Dongtao, ...
(Date:4/1/2015)... and Markets ( http://www.researchandmarkets.com/research/n9mxqs/an_introduction ) has announced ... Medical Device Directives" conference to their offering. ... European medical device legislation. It will explain the Directives ... Bodies, how to choose one and outline what a ... necessary to apply for the CE mark. ...
Breaking Medicine Technology:Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 2Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 3Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 4Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 5Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 2Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 3Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 4Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 5An Introduction to the Medical Device Directives Training: London, UK - 13th, 14th, 15th of May 2015 2
... Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm developing ... infections, announced today the completion of enrollment for a ... vaccine is being developed for use in uninfected people ... virus. The trial, designated HVTN 205, is being conducted ...
... Inc. (NASDAQ: VVUS ) today announced that ... th Annual Scientific Meeting of The Obesity Society ... long-term beneficial effects of Qnexa ® treatment in ... significant improvement in liver function and reductions in medications ...
Cached Medicine Technology:GeoVax Phase 2a Clinical Trial Completes Enrollment 2GeoVax Phase 2a Clinical Trial Completes Enrollment 3GeoVax Phase 2a Clinical Trial Completes Enrollment 4Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 2Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 3Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 4Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 5Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 6
(Date:4/1/2015)... Georgia (PRWEB) April 01, 2015 Boys ... Foundation, a national leader in water safety education, today ... Sandra Deal and the Georgia Children’s Cabinet, that the ... to bring water safety skills and swim instruction to ... called ZAC Camp. The partnership provides swimming-safety instruction ...
(Date:4/1/2015)... EB Medicine, leading publisher of ... Practice, and Hospital Medicine Practice, is pleased to ... provide the content from its flagship publication, ... format available on iPhones, iPads and Android smartphones ... to develop mobile applications for EB Medicine’s journals ...
(Date:4/1/2015)... 01, 2015 SkillSurvey, the leading provider ... talent lifecycle, and the premiere provider of on-line automated ... feature a webinar on “Using Big Data to Recruit ... human resources officer of MorseLife, a nationally recognized provider ... and their families in Palm Beach County. , “As ...
(Date:4/1/2015)... Skin cancer is one of the most ... early. Forefront Dermatology and Dermatology Associates of Wisconsin want to ... it spreads so they are hosting a free skin cancer ... - 12:30pm. , “If we can see the early ... that could become cancerous,” said Dr. Ken Katz, who is ...
(Date:4/1/2015)... Washington, D.C. (PRWEB) April 01, 2015 It ... eaten solely for breakfast but now found wrapped around other ... products. Bacon has been called meat candy, the gateway meat ... as a cultural icon, the North American Meat Institute (NAMI) ... featuring a video tour of a bacon processing plant ...
Breaking Medicine News(10 mins):Health News:Boys & Girls Clubs of America and The ZAC Foundation Announce Third Year of National Partnership to Bring Water Safety Education to 20 Cities Across the Country 2Health News:Boys & Girls Clubs of America and The ZAC Foundation Announce Third Year of National Partnership to Bring Water Safety Education to 20 Cities Across the Country 3Health News:Boys & Girls Clubs of America and The ZAC Foundation Announce Third Year of National Partnership to Bring Water Safety Education to 20 Cities Across the Country 4Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 2Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 3Health News:SkillSurvey Hiring Expert Series Continues with Webinar Featuring MorseLife 2Health News:SkillSurvey Hiring Expert Series Continues with Webinar Featuring MorseLife 3Health News:Forefront Dermatology and Dermatology Associates of Wisconsin Offers Skin Cancer Screenings on April 11th 2Health News:New Ultimate Guide to Bacon Video Provides Inside Look at How Bacon is Made 2
... for growth hormone therapy’s anti-aging powers – says a team ... papers based on growth hormone.// ,'There is certainly ... to an otherwise healthy person will make him or her ... potential for adverse side effects.' - says Dr. Hau Liu, ...
... a member of a large family may not be best ... greatly influenced the development of stomach cancer linked to the ... to be especially vulnerable to the most common type of ... the records of more than 7,000 Japanese-American men who were ...
... have reported an interesting find: statins, or drugs used ... actually have an added benefit; //reduce the chance of ... Australians use pop statins, which are lipid-modifying drugs that ... drug for reducing cholesterol levels. , The drug ...
... ideal world, the answer is no, as breast milk ... ,However, in the same developing countries where the ... is often considered the only safe and nutritious food ... research is needed. ,A new study conducted ...
... true; for fat people and inventors. ,Scientists have always ... Britain are no exception. //Currently, two thirds of the population can ... to put a morbidly obese figure of 2.2 million pounds ... London. ,Bloom’s quest is to create a chewing gum or ...
... chicken eggs that can be used to produce drugs like those ... at Edinburgh, Scotland have claimed to create a flock ... to create life saving drugs. ,These drugs could ... National Health Service incurs, according to them. , For ...
Cached Medicine News:Health News:Is Growth Hormone – a Key to Longevity 2Health News:Link Between Family Size and Stomach Cancer Found 2Health News:Link Between Family Size and Stomach Cancer Found 3Health News:Chew That Fat Away 2Health News:No Pills Just Omelets 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: